| New therapeutic strategy for autoimmune and chronic inflammatory disease based on clinical results using IL-6 blocking therapy with a humanized anti-IL-6 receptor antibody | |
| | |
MedLine Citation:
|
PMID: 19483409 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Remarkable clinical effects were observed by IL-6 blockage with a humanized anti IL-6 receptor antibody in patients with Castleman's disease, rheumatoid arthritis, and juvenile inflammatory arthritis. This evidence suggests that the hyper-function of IL-6 is an essential key cytokine in the pathogenesis of the above diseases, in which many cytokines, chemokines, and inflammatory molecules are activated. We found, for example, TNF-alpha blocking therapy showed a reduction of acute phase proteins, such as CRP and SAA, however, the IL-6 blockade induced not only reduction but also normalization of CRP and SAA serum levels. To elucidate this in vivo phenomenon, we analyzed the expression of cytokine inducing CRP and SAA mRNA with the intracellular signal transduction mechanism in vitro. The results, indicated that the IL-6 signal was essential though the activation of STAT3 for the induction and augmentation of CRP or SAA by the associated stimulation with TNF-alpha or IL-1. Recently, it is now known that IL-6 is a regulatory molecule in the induction of Th17 cells with TGF-beta. Therefore, IL-6 blockage may potentially improve autoimmune diseases, beginning with the pathogenic initiation phase. We believe that unknown pathogenic inflammatory phenomena can be clarified using this analytical strategy and cytokine blocking therapy. Furthermore, in the future we hope to induce complete remission of autoimmune diseases by using cytokine blockage freely. |
| | |
Authors:
|
Kazuyuki Yoshizaki |
Related Documents
:
|
9785039 - Regulation and role of intrapituitary il-6 production by folliculostellate cells. 22819679 - Host-parasite interactions: a litmus test for ocean acidification? 16899109 - Interleukin-6: a new therapeutic target. 18801189 - Ifn-gamma impairs release of il-8 by il-1beta-stimulated a549 lung carcinoma cells. 12562329 - Regulation of epithelial cell cytokine responses by the alpha3beta1 integrin. 15230289 - Rationale for interleukin-6 blockade in systemic lupus erythematosus. 18226169 - Glia as a source of cytokines: implications for neuronal excitability and survival. 23101619 - "transflammation": when innate immunity meets induced pluripotency. 19828129 - Innate immunity of the ocular surface. |
Publication Detail:
|
Type: English Abstract; Journal Article; Review |
Journal Detail:
|
Title: Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan Volume: 129 ISSN: 0031-6903 ISO Abbreviation: Yakugaku Zasshi Publication Date: 2009 Jun |
Date Detail:
|
Created Date: 2009-06-01 Completed Date: 2009-08-06 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0413613 Medline TA: Yakugaku Zasshi Country: Japan |
Other Details:
|
Languages: jpn Pagination: 667-74 Citation Subset: IM |
Affiliation:
|
Center for Advanced Science and Innovation, Osaka University, Osaka, Japan. kyoshi@casi.osaka-u.ac.jp |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Antibodies, Monoclonal / therapeutic use* Autoimmune Diseases / drug therapy*, etiology Chronic Disease Humans Inflammation / drug therapy* Interleukin-6 / physiology Receptors, Interleukin-6 / immunology* |
| Chemical | |
Reg. No./Substance:
|
0/Antibodies, Monoclonal; 0/Interleukin-6; 0/Receptors, Interleukin-6; 0/tocilizumab |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: A new therapeutic approach for autoimmune diseases by the sphingosine 1-phosphate receptor modulator...
Next Document: B Cell Targeting Therapy Using the Anti-CD20 Antibody in Autoimmune Diseases.